North India Statesman
[ad_1]
obesity Nowadays a big problem has become a big problem. Along with obesity, many diseases related to diabetes and heart also increase, which cause health problems. Keeping this problem in mind, Denmark’s drug company Novo Nordisk launched weight loss drug in India on Tuesday. The name of this drug is Vagovi, which is an injectable semaglutide.
This drug is available in various doses
Vegovi, once weekly glucagon-like peptide-1 receptor agonist (GLP-1 RA), is India’s first and only weight-loss drug that provides prolonged weight management and reduces the risk of major adverse cardiovascular events (MACE). It is a pen -like tool that is easy to use. It is available in various doses of 0.25 mg, 0.5 mg, 1 mg, 1.7 mg and 2.4 mg.
How much does it cost?
The cost of the drug starts at Rs 17,345 for 0.25 mg, 0.5 mg and 1 mg, while 1.7 mg is priced at Rs 24,280 per pen and 2.4 mg is priced at Rs 26,015 per pen. The company has said that it is only a medicine available on the prescription. This means that a prescription will be needed to take this medicine. Vegovi can provide relief to millions of Indians suffering from obesity or overweight.
How does the medicine work?
According to a study by IndiaAB, India ranks third in terms of excess weight and number of obesity. The number of people suffering from normal obesity is 254 million, while 351 million people suffer from abdominal obesity.
Wagovi is a GLP-1 receptor agonist. It reduces appetite and reduces the desire to eat. It has a clear effect on weight. It also improves insulin resistance, which improves cardiometabolic systems.
